Aardvark Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing small-molecule therapies for metabolic diseases. Recent 8-K reports cover financial results, pipeline and business updates, ARD-101 HERO trial disclosures in Prader-Willi Syndrome, ARD-201 obesity program updates, clinical protocol matters, and corporate presentation materials.
The filing record also includes capital-structure disclosures tied to a shelf registration statement and equity distribution agreement, governance and executive-transition matters, compensatory arrangements, and the role of Ardia Therapeutics as a wholly owned subsidiary supporting Aardvark's dermatology pipeline.
Aardvark Therapeutics, Inc. (AARD) reported that director Roy D. Baynes received a grant of 44,964 stock options on August 14, 2026. The options have an exercise price of $6.54 per share, expire on August 14, 2036, and are held as a direct ownership position of 44,964 derivative securities. According to the grant terms, the option vests in full on the earlier of August 14, 2027 or immediately prior to the company’s next Annual Meeting of Stockholders following the grant date, subject to his continuous service through the applicable vesting date.
Aardvark Therapeutics, Inc. (AARD) reported that director Victor Edward Tong Jr received a grant of stock options for 44,964 shares of common stock at an exercise price of $6.54 per share. These options vest in full on the earlier of August 14, 2027 or immediately prior to the next Annual Meeting of Stockholders, subject to continuous service, and expire on August 14, 2036. Following this award, Tong holds 44,964 option shares from this grant.
Aardvark Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders held on August 14, 2026. Of 21,884,158 common shares outstanding as of the June 18, 2026 record date, 11,992,479 shares were represented, forming a 54.79% quorum. Stockholders elected Class I directors Victor Tong, Jr. and Jeffrey Chi, Ph.D. to serve until the 2029 annual meeting or until successors are elected and qualified. Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026. In addition, stockholders approved the repricing of certain outstanding stock options under the 2017 Plan, the 2025 Plan and the 2025 Inducement Plan held by eligible participants, based on the stated voting results.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company with no product revenue and an accumulated deficit of $151.9 million as of June 30 2026. For the quarter, it reported a net loss of $14.4 million (basic and diluted net loss per share of $0.66), and for the first six months a net loss of $36.0 million, driven by research and development and public-company overhead.
R&D expense was $10.5 million in the quarter and $27.0 million year‑to‑date; general and administrative expense reached $4.6 million for the quarter and $10.5 million year‑to‑date. Cash, cash equivalents and short‑term investments totaled $73.9 million, and management believes this will fund operations into late 2027. The ARD‑101 program is under an FDA clinical hold; Aardvark terminated its Phase 3 HERO and open‑label extension trials and paused ARD‑201 trials, while evaluating data and required safety studies. The company also established a $150.0 million at‑the‑market equity facility under a $400.0 million shelf registration to provide future financing flexibility.
Aardvark Therapeutics reported second quarter 2026 results and major pipeline developments for ARD-101 in Prader-Willi Syndrome. The company is assessing unblinded Phase 3 HERO and Open Label Extension data in the third quarter of 2026 to determine next steps after terminating both trials in June 2026. In May 2026, the FDA placed a full clinical hold on the ARD-101 investigational new drug application, covering all ongoing studies.
Aardvark held $73.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, which it believes will fund operations into late 2027. Second quarter 2026 research and development expenses were $10.5 million, down from $13.1 million a year earlier, while general and administrative expenses increased to $4.6 million from $2.7 million. Net loss was $14.4 million, consistent with the prior-year quarter, and total assets declined to $81.5 million from $117.2 million at December 31, 2025.
Aardvark Therapeutics, Inc. called a virtual 2026 annual stockholders’ meeting on August 14, 2026 to vote on three proposals. Stockholders will elect two Class I directors, Victor Tong Jr. and Jeffrey Chi, Ph.D., to terms ending at the 2029 meeting, ratify BDO USA, P.C. as independent auditor for the year ending December 31, 2026, and decide on a significant repricing of underwater employee stock options granted under the 2017 Plan, 2025 Plan and 2025 Inducement Plan.
The company had 21,884,158 common shares outstanding as of June 18, 2026, and a quorum requires 10,942,080 shares. As of that date, 99% of options held by eligible employees and executives were underwater; the company proposes to reprice 2,833,944 such options, about 13% of basic shares, to a new exercise price tied to the market price on the “Repricing Date” and subject to a one‑year retention period. The board recommends voting FOR all three proposals.
Aardvark Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on August 14, 2026 to elect two Class I directors, ratify BDO USA, P.C. as auditor and seek stockholder approval to reprice certain outstanding stock options.
The company states there were 21,884,158 shares outstanding as of June 18, 2026. The Option Repricing would amend approximately 2,833,944 Eligible Options (about 13% of issued share capital on a basic outstanding basis) if the computed New Exercise Price is below $13.48. As of June 18, 2026, the closing price was $3.93, and the filing states 99% of outstanding options held by Eligible Participants were underwater.
Aardvark Therapeutics, Inc. approved cash retention arrangements for two senior executives. On June 10, 2026, the company entered into a retention bonus agreement with Chief Financial Officer and Chief Operating Officer Nelson Sun, providing a total potential cash retention bonus of $346,500 for 2026. This consists of a $198,000 guaranteed annual bonus and a $148,500 retention portion, payable on January 1, 2027 if he remains employed through that date or if he experiences certain qualifying terminations.
The company also entered into a similar agreement with Chief Medical Officer Manasi Jaiman, M.D., M.P.H., granting a total retention bonus opportunity of $357,000 for 2026, made up of a $204,000 guaranteed bonus and a $153,000 retention bonus. This amount is also payable on January 1, 2027, subject to continued employment or specified termination conditions, and in each case conditioned on an irrevocable release of claims in a company-prescribed form.
Aardvark Therapeutics disclosed that the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101. The hold covers all ongoing studies, including the Phase 3 HERO trial in Prader-Willi Syndrome and its open-label extension.
The company is in active discussions with the FDA and plans to unblind accumulated data from both HERO and the OLE trial to evaluate overall safety and efficacy and guide next steps for the ARD-101 program. As of February 27, 2026, 68 patients had been dosed in HERO and 19 in the OLE trial.
As of March 31, 2026, Aardvark reported $91.2 million in cash, cash equivalents and short-term investments, which it believes will fund projected operations into mid-2027 while it assesses ARD-101 and continues its broader hunger- and metabolic-disease pipeline.